Purpose of the study was to evaluate the efficiency and duration of clindamycin (Banbact®) therapeutic effect in the treatment of bacterial vaginosis in women of reproductive age.Materials and methods. The study included 47 patients with bacterial vaginosis aged 20–37 years. Vaginal dysbiosis was established on the basis of symptoms indicated by women themselves, results of gynecological examination that was consisting of examination, measurement of vaginal pH based on the Amsels criteria, evaluation of vaginal microbiocenosis by polymerase chain reaction. Treatment was performed with Banbact® – vaginal suppositories clindamycin 100 mg 1 day before bedtime for 6 days.Treatment criteria were no subjective complaints, normal discharge in quantity, odor and consistency; decrease of leukocytes number in smears, secretions pH <4.5, negative amine test, absence of key cells in smears, decrease of pathogenic microflora and increase of lactoflora.Results. On the 14th day after treatment all patients noted a significant improvement in the general condition and decrease in vaginal discharge. Clue cells were detected in only in 1 patient after treatment, accounting for 2.13% of cases. The pH of discharge in all patients was significantly decreased by the 14th day after treatment. There was a clear tendency to reduce the number of G. vaginalis, staphylococci, Mobiluncus spp., A. vaginae, Streptococcus spp. and Staphylococcus spp. and appearance of lactobacilli during treatment. Results of the study show clinical effectiveness of bacterial vaginosis therapy in 93.61% of patients, and laboratory one in 90.12%. Positive effect of therapy persisted for 1 month.Conclusion. Results of the study showed that is clindamycin (Banbact®) is an effective and optimal agent for local therapy of bacterial vaginosis in women of reproductive age. Action spectrum of the antimicrobial and antiseptic drug allows eliminating pathogenic microflora within a short period. There is no systemic effect this drug on the body.